Harbor Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Harbor Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,740	Closed	-$1.93M	–	864
2023 Q4	$1.93M	Sell	4,740 -70	-1%	-$25.9K	0.37%	69
2023 Q3	$1.67M	Hold	4,810	–	–	0.36%	65
2023 Q2	$1.69M	Hold	4,810	–	–	0.34%	71
2023 Q1	$1.52M	Buy	+4,810	New	+$1.44M	0.44%	66

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Harbor Capital Advisors's VRTX Position: Q1 2024 in Review

Harbor Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 4,740 shares — an estimated $1.93M sold.

Harbor Capital Advisors first reported a position in VRTX in Q1 2023 and held it in 4 quarters. The position peaked at $1.93M in Q4 2023. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Harbor Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Harbor Capital Advisors sold 4,740 Vertex Pharmaceuticals shares in Q1 2024, an estimated $1.93M.
Harbor Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 4 quarters.
Harbor Capital Advisors's Vertex Pharmaceuticals position peaked at $1.93M in Q4 2023.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.